Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / chronic weight management | Covered with prior authorization |
| Obstructive sleep apnea (SURMOUNT-OSA indication) | Covered with prior authorization |
Yes, with prior authorization. Highmark's commercial and ACA plans cover Zepbound and Wegovy for weight management under policy J-1388, and Zepbound is the plan-preferred agent. Highmark's own rule is stricter than the drug label: a baseline BMI of 40 or higher plus a qualifying weight-related condition, not the label's BMI 30. A self-funded employer can still carve the benefit out, so confirm your plan includes it before you submit.
Source: Highmark Pharmacy Policy J-1388 Anti-Obesity (Enhanced), Commercial and Healthcare Reform. Verified August 26, 2026.
Plan type: Commercial fully insured and ACA.
What it costs once they say yes. With commercial insurance the manufacturer savings card takes Zepbound or Wegovy to as little as $25 a month. Your plan sets the copay before the card applies. What Zepbound costs with your plan. What Wegovy costs with your plan.
This varies by plan. Highmark covers these drugs under its commercial and ACA pharmacy policy, but a self-funded employer can carve out anti-obesity drugs. Confirm your plan includes the benefit before submitting. The pharmacy benefit manager for most Highmark commercial plans is Express Scripts. Highmark Medicare Advantage follows CMS rules, so pure obesity is not covered and a cardiovascular or sleep-apnea pathway is required.
Coverage by indication
| BMI threshold | Baseline BMI 40 or higher, plus a qualifying weight-related condition. This is Highmark's own coverage rule, stricter than the drug label of BMI 30, or 27 with a comorbidity. |
| Step therapy | Six months of documented diet and physical activity before starting, continued on therapy. Zepbound is the plan-preferred agent, so a request for Wegovy, Saxenda or Foundayo must document intolerance or contraindication to Zepbound first. |
What the prior authorization needs:
- Baseline height, weight, and BMI documentation showing BMI 40 or higher
- One qualifying pathway beyond BMI 40: prediabetes plus high triglycerides plus low HDL (all three together), or one obesity-caused condition such as coronary artery disease or moderate to severe sleep apnea, or at least two conditions from a longer list that includes hypertension, PCOS and severe knee or hip pain
- Six months of diet and physical activity documented before initiation
- Prior authorization is required; the member must not have type 2 diabetes or be taking another GLP-1
Policy J-1388. Source: Highmark Pharmacy Policy J-1388 Anti-Obesity (Enhanced), Commercial and Healthcare Reform. Official payer policy PDF (J-1388-028, effective 07/01/2026, read first-party from securecms.highmark.com and extracted with pdftotext). Verified August 26, 2026.
Under the current policy J-1388, the standalone Zepbound sleep-apnea pathway (BMI 30 or higher, a sleep specialist, and an AHI of 15 or higher) applies only to Delaware commercial and ACA plans that do not include the obesity benefit. For every other Highmark member, moderate to severe sleep apnea instead counts as one qualifying condition under the BMI 40 weight-management pathway above.
| BMI threshold | BMI 30 or higher (standalone sleep-apnea pathway, Delaware plans without an obesity benefit only) |
| Sleep study (AHI) | Moderate to severe OSA, apnea-hypopnea index 15 or higher on a baseline sleep study without PAP |
What the prior authorization needs:
- Prescribed by or in consultation with a sleep specialist
- Moderate to severe OSA diagnosis with baseline AHI of 15 or higher documented
- Current PAP compliance, or documented failure, intolerance or contraindication to PAP
- Reauthorization requires a demonstrated AHI reduction from baseline
Source: Highmark Pharmacy Policy J-1388 Anti-Obesity (Enhanced), Commercial and Healthcare Reform. Official payer policy PDF (J-1388-028, effective 07/01/2026, Section VI, read first-party from securecms.highmark.com). Verified August 26, 2026.
Ozempic, Mounjaro and Rybelsus on Highmark plans
Ozempic, Mounjaro and Rybelsus are approved for type 2 diabetes, not weight loss.
Does Highmark cover Ozempic?
Yes, with prior approval. Highmark pays for Ozempic once your prescriber gets the plan to sign off.
Highmark covers Ozempic for type 2 diabetes on its commercial formularies, usually at Tier 2 with prior authorization and a quantity limit. Ozempic is not covered for weight loss, because it is FDA-approved for type 2 diabetes only. Wegovy is the semaglutide product Highmark covers for weight loss, under a separate weight-loss drug policy that self-insured employers can decline.
Commercial non-Medicare. Verified August 27, 2026.
What Highmark requires for Ozempic
What the prior authorization needs:
- Confirmed type 2 diabetes diagnosis
- Prior authorization required. Highmark drug lists flag Ozempic with a PA marker.
- Quantity limits apply.
- A1C and prior-therapy documentation are typically requested at prior authorization.
- Utilization management varies by the specific Highmark commercial formulary (Comprehensive, National Select, Core). Some formularies apply step therapy through a preferred agent instead of, or alongside, prior authorization.
Source: Highmark Comprehensive Formulary (commercial drug list search). formulary. Verified August 27, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
Does Highmark cover Mounjaro?
Yes, with prior approval. Highmark pays for Mounjaro once your prescriber gets the plan to sign off.
Highmark covers Mounjaro (tirzepatide) for type 2 diabetes on its commercial and ACA (Healthcare Reform) plans under pharmacy policy J-1300. The only stated approval criterion is a documented type 2 diabetes diagnosis (ICD-10 E11), and members who already have a claim for another diabetes drug in the past 720 days are auto-approved at the pharmacy with no prior authorization. Highmark does not cover Mounjaro for weight loss and will not approve it for a sole diagnosis of obesity. Zepbound is the tirzepatide product FDA-approved for weight loss, and it sits under a separate Highmark anti-obesity policy.
Commercial non-Medicare. Verified August 27, 2026.
What Highmark requires for Mounjaro
What the prior authorization needs:
- A documented diagnosis of type 2 diabetes mellitus (ICD-10 E11) is the only approval criterion in the policy.
- Members with a claim for one non-GLP-1 anti-diabetes drug (for example metformin, an SGLT2 inhibitor, or insulin) in the previous 720 days receive automatic approval at the pharmacy with no prior authorization.
- The policy sets no A1C threshold and no mandatory prior-drug failure requirement for approval.
- Approvals last up to 12 months.
- Not approved for a sole diagnosis of obesity. The tirzepatide product for weight loss is Zepbound, covered under a separate anti-obesity policy.
Policy J-1300. Source: Pharmacy Policy Bulletin J-1300: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Diabetes - Commercial and Healthcare Reform. payer_policy. Verified August 27, 2026.
Does Highmark cover Rybelsus?
Yes, with prior approval. Highmark pays for Rybelsus once your prescriber gets the plan to sign off.
Highmark covers Rybelsus for type 2 diabetes under pharmacy policy J-1300. For a member with a documented type 2 diabetes diagnosis (ICD-10 E11) and a pharmacy claim for another non-GLP-1 diabetes drug in the past 720 days, the prior authorization clears automatically at the pharmacy counter. Members without that recent diabetes-drug history need a standard prior authorization. Rybelsus is not covered for weight loss. It is FDA-approved for type 2 diabetes only, and Highmark will not approve it for a sole diagnosis of obesity. Wegovy, the weight-loss semaglutide, is reviewed under Highmark's separate anti-obesity policy.
Commercial non-Medicare. Verified August 28, 2026.
What Highmark requires for Rybelsus
What the prior authorization needs:
- Documented diagnosis of type 2 diabetes (ICD-10 E11).
- The prior authorization clears automatically at the pharmacy point of sale when the member has a claim for one non-GLP-1 diabetes drug (metformin, a sulfonylurea, an SGLT2 inhibitor, insulin, and similar) in the past 720 days. Members without that history need a standard prior authorization.
- Rybelsus is a preferred GLP-1 on this policy, so no step through a second GLP-1 is required.
- Not approved for a sole diagnosis of obesity.
Policy J-1300. Source: Pharmacy Policy Bulletin: J-1300 Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Diabetes - Commercial and Healthcare Reform. payer-policy. Verified August 28, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Start with the Highmark prior-authorization letter template, which cites this plan's policy and the diagnosis codes a reviewer looks for. Pick the indication that matches your clinical picture.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does Highmark cover Zepbound and Wegovy for weight loss?
Yes, with prior authorization. Highmark's commercial and ACA plans cover Zepbound and Wegovy for weight management under policy J-1388, and Zepbound is the plan-preferred agent. Highmark's own rule is stricter than the drug label: a baseline BMI of 40 or higher plus a qualifying weight-related condition, not the label's BMI 30. A self-funded employer can still carve the benefit out, so confirm your plan includes it before you submit. This reflects the published policy verified August 2026.
What does Highmark require to approve Zepbound and Wegovy for weight loss?
For obesity / chronic weight management: The BMI requirement is baseline BMI 40 or higher, plus a qualifying weight-related condition. This is Highmark's own coverage rule, stricter than the drug label of BMI 30, or 27 with a comorbidity.. Six months of documented diet and physical activity before starting, continued on therapy. Zepbound is the plan-preferred agent, so a request for Wegovy, Saxenda or Foundayo must document intolerance or contraindication to Zepbound first.
Why might Highmark deny Zepbound and Wegovy for weight loss even if I meet the criteria?
Highmark covers these drugs under its commercial and ACA pharmacy policy, but a self-funded employer can carve out anti-obesity drugs. Confirm your plan includes the benefit before submitting. The pharmacy benefit manager for most Highmark commercial plans is Express Scripts. Highmark Medicare Advantage follows CMS rules, so pure obesity is not covered and a cardiovascular or sleep-apnea pathway is required.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
